Objectives: Social workers will increasingly be required to attend to the cost-effectiveness of practices, programs, and policies. In the area of substance abuse, there is little evidence to suggest that social workers'decisions are based on evidence of either effectiveness or costs. Method: This article provides an overview of existing evidence on the effectiveness, costs, and benefits of methadone maintenance in the treatment of opiate addiction. Results: Methadone maintenance is a demonstrably cost-effective treatment for heroin dependence. Conclusions: As yet, social workers do not appear to be aware of either the effectiveness or the cost advantages of methadone. Because findings supporting the cost-effectiveness of methadone are stronger than in most areas of social work practice, the extent to which social workers appropriately refer and advocate for clients who can benefit from this treatment can be seen as a bellwether of how the profession will perform in the emerging era of cost-effectiveness.
American Public Health Association. (1997). Support for research on alternative and complementary practices(Policy No. 9714). Available at www.apha.org/legislative/policy/policies.htm
2.
Ball, J., & Ross, A. (1991). The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome. New York: Springer-Verlag.
3.
Barnett, P. G. (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479-488.
4.
Barnett, P. G., & Hui, S. S. (2000). The cost-effectiveness of methadone maintenance. Mount Sinai Journal of Medicine, 67, 365-374.
5.
Booth, B. M., Staton, M., & Leukefeld, C. (2001). Substance use health services research. Substance Use and Misuse, 36, 673-685.
6.
Booth, R. E., Crowley, T. J., & Zhang, Y. (1996). Substance abuse treatment entry, retention and effectiveness: Out-of-treatment injection drug users. Drug and Alcohol Dependence, 42, 11-20.
7.
Center for Substance Abuse Treatment. (1999). Opioid agonist treatment in the 21st century(Center for Substance Abuse Treatment, Office of Pharmacologic and Alternative Therapies Report). Rockville, MD: Substance Abuse and Mental Health Services Administration.
8.
Clark, H. W., Masson, C. L., Delucchi, K. L., Hall, S. M.,& Sees, K. L. (2001). Violent traumatic events and drug abuse severity. Journal of Substance Abuse Treatment, 20, 121-127.
9.
Condelli, W. S., & Hubbard, R. L. (1994). Relationship between time spent in treatment and client outcomes from therapeutic communities. Journal of Substance Abuse Treatment, 11, 25-33.
10.
D'Aunno, T., & Pollack, H. A. (2002). Changes in methadone treatment practices: Results from a national panel study, 1998-2000. Journal of the American Medical Association, 288, 850-856.
11.
El-Bassel, N., Gilbert, L., Witte, S., Wu, E., Gaeta, T., Schilling, R., et al. (2003). Intimate partner violence and substance abuse among minority women receiving care from an inner-city emergency department. Women's Health Issues, 13, 16-22.
12.
El-Bassel, N., Schilling, R. F., Turnbull, J. E.,& Su, K. H. (1993). Correlates of alcohol use among methadone patients. Alcoholism: Clinical and Experimental Research, 17, 681-686.
13.
Farmer, R., & Bentley, K. J. (2002). Social workers as medication facilitators. In K. J. Bentley (Ed.), Social work practice in mental health: Contemporary roles, tasks, and techniques(pp. 211-229). Pacific Grove, CA: Brooks/Cole.
14.
Fortuin Corsi, K., Kwiatkowski, C. F.,& Booth, R. E. (2002, Summer). Predictors of positive outcomes for out-of-treatment opiate injectors recruited into methadone maintenance through street outreach. Journal of Drug Issues. Available at www.findarticles.com/p/articles/mi_qa3733/is_200207/ai_n9105551/pg_1
15.
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., et al. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349, 949-958.
16.
Halpin, L. S., Barnett, S. D.,& Beachy, J. (2003). Cardiac surgery outcomes. Outcomes Management, 7, 144-147.
17.
Hser, Y. I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotics addicts. Archives of General Psychiatry, 58, 503-508.
18.
Hubbard, R. L., & French, M. T. (1991). New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment. NIDA Research Monographs, 113, 94-113.
19.
Hubbard, R. L., Marsden, M. E., Rachal, J. V., Harwood, H. J., Cavanaugh, E. R.,& Ginzburg, H. (1989). Drug abuse treatment: A national study of effectiveness. Chapel Hill: University of North Carolina Press.
20.
Jaudes, P. K., Ekwo, E.,& Van Voohrhis, J. (1995). Association of drug abuse and child abuse. Child Abuse and Neglect, 19, 1065-1075.
21.
Joseph, H., Stancliffe, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine, 67, 347-363.
22.
King, V. L., Stoller, K. B., Hayes, M., Umbricht, A., Currens, M., Kidorf, M. S., et al. (2002). A multicenter randomized evaluation of methadone medical maintenance. Drug Alcohol Dependence, 65, 137-148.
23.
Kosten, T. (1992). Pharmacotherapies. In T. Kosten & H. Kleber (Eds.), Clinician's guide to cocaine addiction: Theory, research, and treatment(pp. 273-289). New York: Guilford.
24.
Lester, B. M., Tronick, E. Z., LaGasse, L., Seifer, R., Bauer, C. R., Shankaran, S., et al. (2002). The Maternal Lifestyle Study: Effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics, 110, 1182-1192.
25.
Lifschltz, M. H.,& Wilson, G. S. (1991). Patterns of growth and development in narcotic-exposed children. NIDA Research Monographs, 114, 323-339.
26.
Ling, W.,& Wesson, D. R. (2003). Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug and Alcohol Dependence, 70(2), S49-S57.
27.
Loneck, B., Garrett, J., & Banks, S. (1997). Engaging and retaining women in outpatient alcohol and other drug treatment. Health and Social Work, 22, 38-46.
28.
Longshore, D., Evans, E., Urada, D., Teruya, C., Hardy, M., Hser, Y. I., et al. (2003). Substance Abuse and Crime Prevention Act 2002 ReportLos Angeles: UCLA Integrated Substance Abuse Programs.
29.
Longshore, D., Hsieh, S., Danila, B., & Anglin, M. D. (1993). Methadone maintenance and needle/syringe sharing. International Journal of Addiction, 28, 983-986.
30.
Lowinson, J., Marion, I., Joseph, H., & Dole, V. (1992). Methadone maintenance. In J. Lowinson, P. Ruiz, R. Millman, & J. Langrod (Eds.), Substance abuse: A comprehensive textbook(pp. 550-561). Baltimore: Williams & Wilkins.
31.
Lundgren, L. M., Schilling, R. F., Fitzgerald, T., Davis, K., & Amodeo, M. (2003). Parental status of women injection drug users and entry to methadone maintenance. Substance Use and Misuse, 38, 1107-1129.
32.
Lundgren, L. M., Schilling, R. F. & Peloquin, S. (2005). Evidencedbased drug treatment practice and the child welfare system: The example of methadone. Social Work, 50(1), 53-63.
33.
Mattick, R. P., Breen, C., Kimber, J.,& Davoli, M. (2003). Methadone maintenance therapy versus no opiate replacement therapy for opiate dependence. Cochrane Database Systematic Review. 2003; (2): CD002209. Review. PMID: 12804430 (Pub Med - indexed for MEDLINE)
34.
Merrill, J. O. (2002). Policy progress for physician treatment of opiate addiction. Journal of General Internal Medicine, 17, 361-368.
35.
Miller, W. R., Rollnick, S.,& Conforti, K. (Eds.). (2002). Motivational interviewing: Preparing people to change addictive behavior(2nd ed.). New York: Guilford.
36.
Mojtabai, R., & Zivin, J. G. (2003). Effectiveness and costeffectiveness of four treatment modalities for substance disorders: A propensity score analysis. Health Services Research, 38, 233-259.
37.
Murphy, S., & Irwin, J. (1992). “Living with the dirty secret”: Problems of disclosure for methadone maintenance clients. Journal of Psychoactive Drugs, 24, 257-264.
38.
National Institute on Drug Abuse. (2000). Principles of drug addiction treatment: A Research-based guide(NIH Publication No. 00-4180,4). Rockville, MD: U.S. Department of Health and Human Services, National Institute on Health.
39.
National Institutes of Health. (1997). Effective medical treatment of opiate addiction(NIH Consensus Statement, November 17-19; 15, 6: 1-38). Kensington, MD: Author.
40.
O'Brien, C. P. (1996). Recent developments in the pharmacotherapy of substance abuse. Journal of Consulting and Clinical Psychology, 64, 677-686.
41.
Pinkerton, S. D., Holtgrave, D. R., DiFranceisco, W., Semaan, S., Coyle, S. L., & Johnson-Masotti, A. P. (2000). Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. AIDS, 14, 1257-1268.
42.
Rawson, R. A., & Obert, J. L. (2002). The substance abuse treatment system in the U.S. What is it? What does it do? Myths and misconceptions. Occupational Medicine, 17, 27-39.
43.
Roebuck, M. C., French, M. T.,& McLellan, A. T. (2003). DATSTats: Results from 85 studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment, 25, 51-57.
44.
Royse, D., Leukefeld, C., Logan, T. K., Dennis, M., Wechsber, W., Hoffman, J., et al. (2000). Homelessness and gender in outoftreatment drug users. American Journal of Drug and Alcohol Abuse, 26, 283-296.
45.
Schilling, R. F., & El-Bassel, N. (1998). Substance abuse interventions. In J. B. Williams & K. Ell (Eds.), Advances in mental health research: Implications for practice(pp. 437-481). Washington, DC: NASW Press.
46.
Schilling, R. F., Mares, A. S., & El-Bassel, N. (2003). Women in detoxification: Loss of guardianship of their children. Children and Youth Services Review, 25(11), 221-225.
47.
Schuckit, M. (1995). Drug and alcohol abuse. New York: Plenum.
48.
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., et al. (2000). Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence. Journal of the American Medical Association, 283, 1303-1310.
49.
Sorensen, J. L., & Copeland, A. L. (2000). Drug abuse treatment as an HIV prevention strategy: A review. Drug and Alcohol Dependence, 59, 17-31.
50.
Stucker, S. (2000). Drug abuse treatment programs make gains in methadone treatment and HIV prevention. NIDA Notes, 15, 3-3.
51.
Substance Abuse and Mental Health Services Administration. (2003a). The ADSS cost study: Costs of substance abuse treatment in the specialty sector(DHHS Publication No. SMA 03-3762, Analytic Series A-20). Rockville, MD: Office of Applied Studies, Health and Human Services.
52.
Substance Abuse and Mental Health Services Administration. (2003b). Planned methadone treatment for heroin admissions(The DASIS Report, June 13). Arlington, VA: Office of Applied Studies, Health and Human Services.
53.
Tims, E., Leukefeld, C., & Platt, J. (Eds.). (2001). Relapse and recovery processes in the addictions. New Haven, CT: Yale University Press.
54.
Turner, B. J., Newschaffer, C. J., Zhang, D., Fanning, T., & Hauck, W. W. (1999). Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women. Annals of Internal Medicine, 130, 979-986.
55.
Van Beusekom, I.,& Iguchi, M. Y. (2001). A reviewof recent advances in knowledge about methadone maintenance treatment(MR-1396/ RE/FOPH/DPRC). Leiden, The Netherlands: Drug Policy Research Center, RAND Europe.
56.
Vastag, B. (2003). Addiction poorly understood by clinicians: Experts say attitudes, lack of knowledge hinder treatment. Journal of the American Medical Association, 290, 1299-1303.
57.
World Health Organization. (2001). Summary of papers: XII International AIDS Conference. Available at www.who.int/HIV_AIDS/IDU/IDU_summary.html
58.
Zaric, G. S., Barnett, P. G., & Brandeau, M. L. (2000). HIV transmission and the cost-effectiveness of methadone maintenance. American Journal of Public Health, 90, 1100-1111.
59.
Ziegler, M., Poustka, F., von Loewenich, V., & Englert, E. (2000). Postpartum risk factors in the development of children born to opiate-addicted mothers: Comparison between mothers with and without methadone substitution. Nervenarzt, 71, 730-736.
